On February 27, 2024, Allarity Therapeutics, Inc. entered into an amendment to their Senior Convertible Notes with 3i, LP. The amendment to the notes, originally dated January 18, 2024, and February 13, 2024, modifies Section 4(c)(vi) to prevent the Holder from converting the notes to common stock if such conversion would require stockholder approval or exceed 19.9% of the common stock shares. All other terms of the Notes remain unchanged. Additionally, on March 1, 2024, Allarity Therapeutics updated their corporate presentation slides and made them available on the company's website. These slides are intended for use in presentations to investors, analysts, and other interested parties. The information provided in the corporate presentation is furnished and not filed, nor is it incorporated by reference into any filing under the Securities Act or the Exchange Act.

On February 27, 2024, Allarity Therapeutics, Inc. entered into an amendment to their Senior Convertible Notes with 3i, LP. The amendment to the notes, originally dated January 18, 2024, and February 13, 2024, modifies Section 4(c)(vi) to prevent the Holder from converting the notes to common stock if such conversion would require stockholder approval or exceed 19.9% of the common stock shares. All other terms of the Notes remain unchanged. Additionally, on March 1, 2024, Allarity Therapeutics updated their corporate presentation slides and made them available on the company's website. These slides are intended for use in presentations to investors, analysts, and other interested parties. The information provided in the corporate presentation is furnished and not filed, nor is it incorporated by reference into any filing under the Securities Act or the Exchange Act.